GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Net Margin %
中文

Molecular Templates (Molecular Templates) Net Margin % : -59.47% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Molecular Templates Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Molecular Templates's Net Income for the three months ended in Dec. 2023 was $-3.95 Mil. Molecular Templates's Revenue for the three months ended in Dec. 2023 was $6.64 Mil. Therefore, Molecular Templates's net margin for the quarter that ended in Dec. 2023 was -59.47%.

The historical rank and industry rank for Molecular Templates's Net Margin % or its related term are showing as below:

MTEM' s Net Margin % Range Over the Past 10 Years
Min: -960.96   Med: -356.02   Max: 56.97
Current: -15.44


MTEM's Net Margin % is ranked better than
69.4% of 1026 companies
in the Biotechnology industry
Industry Median: -163.08 vs MTEM: -15.44

Molecular Templates Net Margin % Historical Data

The historical data trend for Molecular Templates's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Net Margin % Chart

Molecular Templates Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -356.02 -671.03 -214.51 -469.36 -15.44

Molecular Templates Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -844.47 32.25 -164.00 -72.45 -59.47

Competitive Comparison of Molecular Templates's Net Margin %

For the Biotechnology subindustry, Molecular Templates's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Templates's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Templates's Net Margin % distribution charts can be found below:

* The bar in red indicates where Molecular Templates's Net Margin % falls into.



Molecular Templates Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Molecular Templates's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-8.124/52.625
=-15.44 %

Molecular Templates's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.948/6.639
=-59.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Templates  (NAS:MTEM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Molecular Templates Net Margin % Related Terms

Thank you for viewing the detailed overview of Molecular Templates's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Templates (Molecular Templates) Business Description

Traded in Other Exchanges
N/A
Address
9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.
Executives
Maurizio Voi officer: Chief Medical Officer 4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan officer: CFO & Treasurer C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande director, 10 percent owner 201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc 10 percent owner FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim officer: See Remarks 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch director, 10 percent owner C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p. 10 percent owner 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein director C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019

Molecular Templates (Molecular Templates) Headlines

From GuruFocus

Molecular Templates Announces Participation in Upcoming Conferences

By sperokesalga sperokesalga 03-01-2023

Molecular Templates to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-06-2022

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-21-2022